研究表明,5%~10%的乳腺癌患者具有明确的遗传基因突变,称之为遗传性乳腺癌(hereditary breast cancer,HBC),其中BRCA1基因突变占30-35%,BRCA2基因突变占20-25%。 携带BRCA1/2基因突变的女性不仅乳腺癌发病风险增加,其他如卵巢癌、输卵管癌、胰腺癌、胃肠...
17. A.W. Kurian, P. Abrahamse, A.S. Hamilton, et al. Chemotherapy regimens received by women with BRCA1/2 pathogenic variants for early stage breast cancer treatment. JNCI Cancer Spectr, 6 (4) (2022), p. pkac045 CN-...
但BRCA突变细胞对PARP抑制剂具有高度敏感性,PARP抑制剂的出现对于BRCA突变患者来说不仅仅是找到了一种针对该突变的治疗方法,同时也可以判断与其他治疗之间的相关性。比如ESMO大会的一个报告中提到,对于BRCA2突变的患者(HR阳性乳腺癌患者大部分突变类型为BRCA2突变),CDK4/6抑制剂与PARP抑制剂的使用谁先谁后的问题。所...
Breast cancer, one of the most common serious malignancies affecting women, occurs in hereditary and sporadic forms. Hereditary breast cancer accounts for
美国德克萨斯大学M.D.Anderson 学习2年 中国女医师协会乳腺专业委员会主任委员 中华医学会乳腺学组副组长 中国抗癌协会乳腺癌专业委员会常委 中国女医师协会临床肿瘤学专委会副主任委员 中国进展期乳腺癌共识指南共同组长和执笔人 Associate Editor of “Breast Cancer Research and Treatment” ...
为了填补这一空白,来自以色列 Sheba Tel Hashomer 医疗中心等多个机构的研究人员 Rinat Bernstein - Molho、Ory Haisraely 等开展了一项重要研究。该研究成果发表在《Breast Cancer Research and Treatment》杂志上,为乳腺癌治疗领域带来了新的曙光。 研究方法:抽丝剥茧,探寻真相 ...
For women with breast cancer and a germline BRCA2 mutation, positive ER status does not predict superior survival. Oophorectomy is associated with a reduced risk of death from breast cancer and should be considered in the treatment plan.
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitorsHeterozygous germline mutations inpredispose to breast and ovarian cancer. Contrary to non-cancerous cells, wheredeletion causes cell cycle arrest or cell death, tumors carryinginactivation continue to proliferate....
Olaparib as Adjuvant Treatment in Patients with Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA). Available at: https://clinicaltrials.gov/ct2/show/NCT02032823. Accessed October 2024. [13]Roy R, et al. BRCA1 and BRCA2: different roles in a common pathway of ...
[7] Grinda T, Delaloge S. BRCA2: a 25-year journey from gene identification to targeted cancer treatment. Lancet Oncol. 2021;22(6):763-764. doi:10.1016/S1470-2045(21)00272-2 [8] Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening...